Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
REVENUES:        
Product revenue $ 4,693,703 $ 2,902,155 $ 10,650,558 $ 7,226,368
License and other revenue 35,708 35,708 107,125 107,125
Total Revenues 4,729,411 2,937,863 10,757,683 7,333,493
OPERATING EXPENSES        
Cost of product revenue (exclusive of amortization expense shown below) 11,291,116 1,735,771 17,241,422 4,346,433
Research and development 1,814,069 1,677,263 4,365,205 7,104,864
Plasma centers 1,582,694 1,482,586 4,662,340 4,057,306
Amortization of intangibles 273,828 0 346,849 0
Selling, general and administrative 4,195,464 1,779,115 12,908,498 5,211,148
TOTAL OPERATING EXPENSES 19,157,171 6,674,735 39,524,314 20,719,751
LOSS FROM OPERATIONS (14,427,760) (3,736,872) (28,766,631) (13,386,258)
OTHER INCOME (EXPENSE):        
Interest income 8,014 11,605 34,440 37,130
Interest expense (782,969) (605,972) (2,043,982) (1,611,411)
Other income 0 0 0 4,496
OTHER EXPENSE, NET (774,955) (594,367) (2,009,542) (1,569,785)
NET LOSS $ (15,202,715) $ (4,331,239) $ (30,776,173) $ (14,956,043)
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.59) $ (0.34) $ (1.67) $ (1.26)
WEIGHTED AVERAGE SHARES OUTSTANDING, Basic and Diluted 25,790,805 12,886,741 18,415,468 11,906,276